Citations

Citations to this article as recorded by  

• Expression of STAT3, IL27p28 and IL12p35 is deregulated and linked to autoimmune markers in chronic spontaneous urticaria
  Sahar Rastgoo, Mojgan Mohammadi, Marcus Maurer, Mahdi Atabaki, Jalil Tavakkol-Afshari, Maryam Khoshkhui
  Clinical and Experimental Dermatology.2025; 50(2): 357.     CrossRef
• Insights into IL-6/JAK/STAT3 signaling in the tumor microenvironment: Implications for cancer therapy
  Win Lwin Thuya, Yang Cao, Paul Chi-Lui Ho, Andrea Li-Ann Wong, Lingzhi Wang, Jianbiao Zhou, Christophe Nicot, Boon Cher Goh
  Cytokine & Growth Factor Reviews.2025;[Epub]     CrossRef
• CTSL Promotes Autophagy in Laryngeal Cancer Through the IL6‐JAK‐STAT3 Signalling Pathway
  Xueying Wang, Junrong Wang, Lei Wang, Ming Song, Hongxue Meng, Erliang Guo, Susheng Miao
  Journal of Cellular and Molecular Medicine.2025;[Epub]     CrossRef
• Hepatocellular carcinoma: signaling pathways and therapeutic advances
  Jiaojiao Zheng, Siying Wang, Lei Xia, Zhen Sun, Kui Ming Chan, René Bernards, Wenxin Qin, Jinhong Chen, Qiang Xia, Haojie Jin
  Signal Transduction and Targeted Therapy.2025;[Epub]     CrossRef
• STAT3 Inhibition Prevents Adaptive Resistance and Augments NK Cell Cytotoxicity to KRASG12C Inhibitors in Nonsmall Cell Lung Cancer
  Zehao Pan, Yuxian Qian, Yajing Wang, Te Zhang, Xuming Song, Hanling Ding, Rutao Li, Yijian Zhang, Zi Wang, Hui Wang, Wenjie Xia, Lei Wei, Lin Xu, Gaochao Dong, Feng Jiang
  Cancer Science.2025;[Epub]     CrossRef
• STAT signaling in the pathogenesis and therapy of acute myeloid leukemia and myelodysplastic syndromes
  Zoe King, Sudhamsh Reddy Desai, David A. Frank, Aditi Shastri
  Neoplasia.2025; 61: 101137.     CrossRef
• Unraveling the complexity of STAT3 in cancer: molecular understanding and drug discovery
  Yamei Hu, Zigang Dong, Kangdong Liu
  Journal of Experimental & Clinical Cancer Research.2024;[Epub]     CrossRef
• Hepatocellular Carcinoma: Old and Emerging Therapeutic Targets
  Greta Pessino, Claudia Scotti, Maristella Maggi
  Cancers.2024; 16(5): 901.     CrossRef
• Impact of STAT-signaling pathway on cancer-associated fibroblasts in colorectal cancer and its role in immunosuppression
  Damián Sánchez-Ramírez, Mónica G Mendoza-Rodríguez, Omar R Alemán, Fernando A Candanedo-González, Miriam Rodríguez-Sosa, Juan José Montesinos-Montesinos, Mauricio Salcedo, Ismael Brito-Toledo, Felipe Vaca-Paniagua, Luis I Terrazas
  World Journal of Gastrointestinal Oncology.2024; 16(5): 1705.     CrossRef
• Targeted Treatment against Cancer Stem Cells in Colorectal Cancer
  Julia Martínez-Pérez, Carlos Torrado, María A. Domínguez-Cejudo, Manuel Valladares-Ayerbes
  International Journal of Molecular Sciences.2024; 25(11): 6220.     CrossRef
• Interleukin-6 serves as a critical factor in various cancer progression and therapy
  Asma’a H. Mohamed, Abdulrahman T. Ahmed, Waleed Al Abdulmonem, Dmitry Olegovich Bokov, Alaa Shafie, Hussein Riyadh Abdul Kareem Al-Hetty, Chou-Yi Hsu, Mohammed Alissa, Shahid Nazir, Mohammad Chand Jamali, Mustafa Mudhafar
  Medical Oncology.2024;[Epub]     CrossRef
• Targeting cytokine and chemokine signaling pathways for cancer therapy
  Ming Yi, Tianye Li, Mengke Niu, Haoxiang Zhang, Yuze Wu, Kongming Wu, Zhijun Dai
  Signal Transduction and Targeted Therapy.2024;[Epub]     CrossRef
• Recent advances in targeted drug delivery systems for multiple myeloma
  Ashruti Pant, Aayushi Laliwala, Sarah A. Holstein, Aaron M. Mohs
  Journal of Controlled Release.2024; 376: 215.     CrossRef
• A strategic review of STAT3 signaling inhibition by phytochemicals for cancer prevention and treatment: Advances and insights
  Suryaa Manoharan, Ekambaram Perumal
  Fitoterapia.2024; 179: 106265.     CrossRef
• The STAT family: Key transcription factors mediating crosstalk between cancer stem cells and tumor immune microenvironment
  Mengxuan Zhu, Suyao Li, Xin Cao, Khalid Rashid, Tianshu Liu
  Seminars in Cancer Biology.2023; 88: 18.     CrossRef
• Dual inhibition of MYC and SLC39A10 by a novel natural product STAT3 inhibitor derived from Chaetomium globosum suppresses tumor growth and metastasis in gastric cancer
  Xiaoqing Guan, Jing Yang, Weiyi Wang, Bing Zhao, Shiyu Hu, Dehua Yu, Li Yuan, Yunfu Shi, Jingli Xu, Jinyun Dong, Jinxin Wang, Xiang-Dong Cheng, Jiang-Jiang Qin
  Pharmacological Research.2023; 189: 106703.     CrossRef
• JAK/STAT pathway: Extracellular signals, diseases, immunity, and therapeutic regimens
  Qian Hu, Qihui Bian, Dingchao Rong, Leiyun Wang, Jianan Song, Hsuan-Shun Huang, Jun Zeng, Jie Mei, Peng-Yuan Wang
  Frontiers in Bioengineering and Biotechnology.2023;[Epub]     CrossRef
• Brevilin A is a potent anti-metastatic CRC agent that targets the VEGF-IL6-STAT3 axis in the HSCs-CRC interplay
  Xueying Fan, Mingjing Meng, Baoting Li, Hui Chen, Jincheng Tan, Keyang Xu, Shilin Xiao, Hiu-Yee Kwan, Zhongqiu Liu, Tao Su
  Journal of Translational Medicine.2023;[Epub]     CrossRef
• Application of Nano-Antibodies for Cancer Immunotherapy
  Sunanda Singh, Samara P. Singh, Ashutosh S. Parihar
  Current Tissue Microenvironment Reports.2023; 4(2): 17.     CrossRef
• Exploring the dynamic interplay between cancer stem cells and the tumor microenvironment: implications for novel therapeutic strategies
  Yan-Ruide Li, Ying Fang, Zibai Lyu, Yichen Zhu, Lili Yang
  Journal of Translational Medicine.2023;[Epub]     CrossRef
• C188-9, a specific inhibitor of STAT3 signaling, prevents thermal burn-induced skeletal muscle wasting in mice
  Yuko Ono, Masafumi Saito, Kazuho Sakamoto, Yuko Maejima, Shingen Misaka, Kenju Shimomura, Nobuto Nakanishi, Shigeaki Inoue, Joji Kotani
  Frontiers in Pharmacology.2022;[Epub]     CrossRef
• Signaling Pathways and Targeted Therapies for Stem Cells in Prostate Cancer
  Madhuvanthi Giridharan, Vasu Rupani, Satarupa Banerjee
  ACS Pharmacology & Translational Science.2022; 5(4): 193.     CrossRef
• Insights into the role of STAT3 in intrahepatic cholangiocarcinoma (Review)
  Ranzhiqiang Yang, Yinghui Song, Kashif Shakoor, Weimin Yi, Chuang Peng, Sulai Liu
  Molecular Medicine Reports.2022;[Epub]     CrossRef
• Inhibition of STAT3-ferroptosis negative regulatory axis suppresses tumor growth and alleviates chemoresistance in gastric cancer
  Shumin Ouyang, Huaxuan Li, Linlin Lou, Qiuyao Huang, Zhenhua Zhang, Jianshan Mo, Min Li, Jiaye Lu, Kai Zhu, Yunjie Chu, Wen Ding, Jianzheng Zhu, Ziyou Lin, Lin Zhong, Junjian Wang, Peibin Yue, James Turkson, Peiqing Liu, Yuanxiang Wang, Xiaolei Zhang
  Redox Biology.2022; 52: 102317.     CrossRef
• Digesting the Role of JAK-STAT and Cytokine Signaling in Oral and Gastric Cancers
  Yanhong Ni, Jun T. Low, John Silke, Lorraine A. O’Reilly
  Frontiers in Immunology.2022;[Epub]     CrossRef
• A Broad-Based Characterization of a Cell-Penetrating, Single Domain Camelid Bi-Specific Antibody Monomer That Targets STAT3 and KRAS Dependent Cancers
  Sunanda Singh, Genoveva Murillo, Justin Richner, Samara P. Singh, Erica Berleth, Vijay Kumar, Rajendra Mehta, Vijay Ramiya, Ashutosh S. Parihar
  International Journal of Molecular Sciences.2022; 23(14): 7565.     CrossRef
• Molecular mechanisms underlying the action of carcinogens in gastric cancer with a glimpse into targeted therapy
  Elham Patrad, Solmaz Khalighfard, Taghi Amiriani, Vahid Khori, Ali Mohammad Alizadeh
  Cellular Oncology.2022; 45(6): 1073.     CrossRef
• STAT3 and Its Targeting Inhibitors in Oral Squamous Cell Carcinoma
  Mingjing Jiang, Bo Li
  Cells.2022; 11(19): 3131.     CrossRef
• The Role of IL-6 in Cancer Cell Invasiveness and Metastasis—Overview and Therapeutic Opportunities
  Magdalena Rašková, Lukáš Lacina, Zdeněk Kejík, Anna Venhauerová, Markéta Skaličková, Michal Kolář, Milan Jakubek, Daniel Rosel, Karel Smetana, Jan Brábek
  Cells.2022; 11(22): 3698.     CrossRef
• An update on investigational therapies that target STAT3 for the treatment of cancer
  Matteo Santoni, Francesca Miccini, Alessia Cimadamore, Francesco Piva, Francesco Massari, Liang Cheng, Antonio Lopez-Beltran, Rodolfo Montironi, Nicola Battelli
  Expert Opinion on Investigational Drugs.2021; 30(3): 245.     CrossRef
• RETRACTED: GATA4 Regulates Inflammation-Driven Pancreatic Ductal Adenocarcinoma Progression
  Weiliang Jiang, Congying Chen, Li Huang, Jie Shen, Lijuan Yang
  Frontiers in Cell and Developmental Biology.2021;[Epub]     CrossRef
• Phytochemicals Targeting JAK–STAT Pathways in Inflammatory Bowel Disease: Insights from Animal Models
  Sun Young Moon, Kwang Dong Kim, Jiyun Yoo, Jeong-Hyung Lee, Cheol Hwangbo
  Molecules.2021; 26(9): 2824.     CrossRef
• Development and Validation of an IL6/JAK/STAT3-Related Gene Signature to Predict Overall Survival in Clear Cell Renal Cell Carcinoma
  Chuanchuan Zhan, Chao Xu, Jiajun Chen, Chong Shen, Jinkun Li, Zichu Wang, Xiangrong Ying, Zhengang Luo, Yu Ren, Gangfeng Wu, Haojie Zhang, Manfei Qian
  Frontiers in Cell and Developmental Biology.2021;[Epub]     CrossRef
• Emerging role of signal transducer and activator of transcription 3 (STAT3) in pituitary adenomas
  Cyndy Liu, Tae Nakano-Tateno, Motoyasu Satou, Constance Chik, Toru Tateno
  Endocrine Journal.2021; 68(10): 1143.     CrossRef
• The JAK/STAT signaling pathway: from bench to clinic
  Xiaoyi Hu, Jing li, Maorong Fu, Xia Zhao, Wei Wang
  Signal Transduction and Targeted Therapy.2021;[Epub]     CrossRef
• Interleukin-6 and colorectal cancer development
  I.А. Hromakova, P.P. Sorochan, N.E. Prokhach, I.S. Hromakova
  Український радіологічний та онкологічний журнал.2021; 29(4): 89.     CrossRef
• Ailanthone suppresses the activity of human colorectal cancer cells through the STAT3 signaling pathway
  Haixiang Ding, Xiuchong Yu, Zhilong Yan
  International Journal of Molecular Medicine.2021;[Epub]     CrossRef
• Radiation induces an inflammatory response that results in STAT3-dependent changes in cellular plasticity and radioresistance of breast cancer stem-like cells
  Kimberly M. Arnold, Lynn M. Opdenaker, Nicole J. Flynn, Daniel Kwesi Appeah, Jennifer Sims-Mourtada
  International Journal of Radiation Biology.2020; 96(4): 434.     CrossRef
• Quinazoline Ligands Induce Cancer Cell Death through Selective STAT3 Inhibition and G-Quadruplex Stabilization
  Jan Jamroskovic, Mara Doimo, Karam Chand, Ikenna Obi, Rajendra Kumar, Kristoffer Brännström, Mattias Hedenström, Rabindra Nath Das, Almaz Akhunzianov, Marco Deiana, Kazutoshi Kasho, Sebastian Sulis Sato, Parham L. Pourbozorgi, James E. Mason, Paolo Medini
  Journal of the American Chemical Society.2020; 142(6): 2876.     CrossRef
• Phosphotyrosine isosteres: past, present and future
  Robert A. Cerulli, Joshua A. Kritzer
  Organic & Biomolecular Chemistry.2020; 18(4): 583.     CrossRef
• Anticancer activity of dietary xanthone α-mangostin against hepatocellular carcinoma by inhibition of STAT3 signaling via stabilization of SHP1
  Hai Zhang, Yu-ping Tan, Lin Zhao, Lun Wang, Nai-jie Fu, Song-ping Zheng, Xiao-fei Shen
  Cell Death & Disease.2020;[Epub]     CrossRef
• JAK/STAT signaling in hepatocellular carcinoma
  Justin Jit Hin Tang, Dexter Kai Hao Thng, Jhin Jieh Lim, Tan Boon Toh
  Hepatic Oncology.2020;[Epub]     CrossRef
• JAK–STAT pathway targeting for the treatment of inflammatory bowel disease
  Azucena Salas, Cristian Hernandez-Rocha, Marjolijn Duijvestein, William Faubion, Dermot McGovern, Severine Vermeire, Stefania Vetrano, Niels Vande Casteele
  Nature Reviews Gastroenterology & Hepatology.2020; 17(6): 323.     CrossRef
• Targeting STAT3 in cancer and autoimmune diseases
  Tohid Gharibi, Zohreh Babaloo, Arezoo Hosseini, Meghdad Abdollahpour-alitappeh, Vida Hashemi, Faroogh Marofi, Kazem Nejati, Behzad Baradaran
  European Journal of Pharmacology.2020; 878: 173107.     CrossRef
• Betacellulin drives therapy resistance in glioblastoma
  Qiwen Fan, Zhenyi An, Robyn A Wong, Xujun Luo, Edbert D Lu, Albert Baldwin, Manasi K Mayekar, Franziska Haderk, Kevan M Shokat, Trever G Bivona, William A Weiss
  Neuro-Oncology.2020; 22(4): 457.     CrossRef
• A novel small molecule STAT3 inhibitor SLSI-1216 suppresses proliferation and tumor growth of triple-negative breast cancer cells through apoptotic induction
  Soo Kyung Park, Woong Sub Byun, Seungbeom Lee, Young Taek Han, Yoo-Seong Jeong, Kyungkuk Jang, Suk-Jae Chung, Jeeyeon Lee, Young-Ger Suh, Sang Kook Lee
  Biochemical Pharmacology.2020; 178: 114053.     CrossRef
• STAT3 Pathway in Gastric Cancer: Signaling, Therapeutic Targeting and Future Prospects
  Milad Ashrafizadeh, Ali Zarrabi, Sima Orouei, Vahideh Zarrin, Ebrahim Rahmani Moghadam, Amirhossein Zabolian, Shima Mohammadi, Kiavash Hushmandi, Yashar Gharehaghajlou, Pooyan Makvandi, Masoud Najafi, Reza Mohammadinejad
  Biology.2020; 9(6): 126.     CrossRef
• Towards the Inhibition of Protein–Protein Interactions (PPIs) in STAT3: Insights into a New Class of Benzothiadiazole Derivatives
  Matteo Mori, Ettore Gilardoni, Luca Regazzoni, Alessandro Pedretti, Diego Colombo, Gary Parkinson, Akira Asai, Fiorella Meneghetti, Stefania Villa, Arianna Gelain
  Molecules.2020; 25(15): 3509.     CrossRef
• STAT3, the Challenge for Chemotherapeutic and Radiotherapeutic Efficacy
  Ping-Lian Yang, Lu-Xin Liu, En-Min Li, Li-Yan Xu
  Cancers.2020; 12(9): 2459.     CrossRef

• Progress in Understanding the IL-6/STAT3 Pathway in Colorectal Cancer

  
  Yan Lin, Ziqin He, Jiazhou Ye, Ziyu Liu, Xiaomin She, Xing Gao, Rong Liang
  OncoTargets and Therapy.2020; Volume 13: 13023.     CrossRef
• Systemic Therapy for Hepatocellular Carcinoma: Advances and Hopes
  Chen-Hao Zhang, Ming Li, You-Pei Lin, Qiang Gao
  Current Gene Therapy.2020; 20(2): 84.     CrossRef
• Decoration of Anti-CD38 on Nanoparticles Carrying a STAT3 Inhibitor Can Improve the Therapeutic Efficacy Against Myeloma
  Yung-Hsing Huang, Mohammad Reza Vakili, Ommoleila Molavi, Yuen Morrissey, Chengsheng Wu, Igor Paiva, Amir Hasan Soleimani, Forugh Sanaee, Afsaneh Lavasanifar, Raymond Lai
  Cancers.2019; 11(2): 248.     CrossRef
• Phase I Dose-Finding Study of OPB-111077, a Novel STAT3 Inhibitor, in Patients with Advanced Hepatocellular Carcinoma
  Changhoon Yoo, Jihoon Kang, Ho Yeong Lim, Jee Hyun Kim, Myung-Ah Lee, Kyung-Hun Lee, Tae-You Kim, Baek-Yeol Ryoo
  Cancer Research and Treatment.2019; 51(2): 510.     CrossRef
• IL-6 signaling contributes to radioresistance of prostate cancer through key DNA repair-associated molecules ATM, ATR, and BRCA 1/2
  Xiaodong Chen, Feng Chen, Yu Ren, Guobin Weng, Lijun Xu, Xiang Xue, Peter C. Keng, Soo Ok Lee, Yuhchyau Chen
  Journal of Cancer Research and Clinical Oncology.2019; 145(6): 1471.     CrossRef
• Proton pump inhibitor: The dual role in gastric cancer
  Moon Kyung Joo, Jong-Jae Park, Hoon Jai Chun
  World Journal of Gastroenterology.2019; 25(17): 2058.     CrossRef
• Transcriptional Reprogramming and Novel Therapeutic Approaches for Targeting Prostate Cancer Stem Cells
  Gianluca Civenni, Domenico Albino, Dheeraj Shinde, Ramiro Vázquez, Jessica Merulla, Aleksandra Kokanovic, Sarah N. Mapelli, Giuseppina M. Carbone, Carlo V. Catapano
  Frontiers in Oncology.2019;[Epub]     CrossRef
• STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review
  Jiang-Jiang Qin, Li Yan, Jia Zhang, Wei-Dong Zhang
  Journal of Experimental & Clinical Cancer Research.2019;[Epub]     CrossRef
• JAK/STAT inhibition in macrophages promotes therapeutic resistance by inducing expression of protumorigenic factors
  Emily A. Irey, Chelsea M. Lassiter, Nicholas J. Brady, Pavlina Chuntova, Ying Wang, Todd P. Knutson, Christine Henzler, Thomas S. Chaffee, Rachel I. Vogel, Andrew C. Nelson, Michael A. Farrar, Kathryn L. Schwertfeger
  Proceedings of the National Academy of Sciences.2019; 116(25): 12442.     CrossRef
• Elevated HOX gene expression in acute myeloid leukemia is associated with NPM1 mutations and poor survival
  Ádám Nagy, Ágnes Ősz, Jan Budczies, Szilvia Krizsán, Gergely Szombath, Judit Demeter, Csaba Bödör, Balázs Győrffy
  Journal of Advanced Research.2019; 20: 105.     CrossRef
• Antitumor activity of novel pyrazole-based small molecular inhibitors of the STAT3 pathway in patient derived high grade glioma cells
  Liang Zhang, Timothy E. Peterson, Victor M. Lu, Ian F. Parney, David J. Daniels, Ilya Ulasov
  PLOS ONE.2019; 14(7): e0220569.     CrossRef
• Inhibition of Stat3 Signaling Pathway by Natural Product Pectolinarigenin Attenuates Breast Cancer Metastasis
  Yali Li, Cailing Gan, Yange Zhang, Yan Yu, Chen Fan, Yuanle Deng, Qianyu Zhang, Xi Yu, Yiwen Zhang, Liqun Wang, Fang He, Yongmei Xie, Tinghong Ye, Wenya Yin
  Frontiers in Pharmacology.2019;[Epub]     CrossRef
• Impact of combination therapy with anti-PD-1 blockade and a STAT3 inhibitor on the tumor-infiltrating lymphocyte status
  Tadashi Ashizawa, Akira Iizuka, Chie Maeda, Emiko Tanaka, Ryota Kondou, Haruo Miyata, Takashi Sugino, Takuya Kawata, Shoichi Deguchi, Koichi Mitsuya, Nakamasa Hayashi, Akira Asai, Mamoru Ito, Ken Yamaguchi, Yasuto Akiyama
  Immunology Letters.2019; 216: 43.     CrossRef
• Signal Transducer and Activator of Transcription Protein 3 (STAT3): An Update on its Direct Inhibitors as Promising Anticancer Agents
  Arianna Gelain, Matteo Mori, Fiorella Meneghetti, Stefania Villa
  Current Medicinal Chemistry.2019; 26(27): 5165.     CrossRef
• The effects of signal transducer and activator of transcription three mutations on human platelets
  Floor E. Aleva, Frank L. van de Veerdonk, Yang Li, Rahajeng N. Tunjungputri, Sami Simons, Philip G. De Groot, Mihai M. Netea, Yvonne F. Heijdra, Quirijn de Mast, André J.A.M. van der Ven
  Platelets.2018; 29(6): 602.     CrossRef
• Mechanisms Linking Obesity and Thyroid Cancer Development and Progression in Mouse Models
  Won Gu Kim, Sheue-yann Cheng
  Hormones and Cancer.2018; 9(2): 108.     CrossRef
• Targeting the IL-6/JAK/STAT3 signalling axis in cancer
  Daniel E. Johnson, Rachel A. O'Keefe, Jennifer R. Grandis
  Nature Reviews Clinical Oncology.2018; 15(4): 234.     CrossRef
• Arsenic trioxide attenuates STAT-3 activity and epithelial-mesenchymal transition through induction of SHP-1 in gastric cancer cells
  Sung Ho Kim, Hyo Soon Yoo, Moon Kyung Joo, Taehyun Kim, Jong-Jae Park, Beom Jae Lee, Hoon Jai Chun, Sang Woo Lee, Young-Tae Bak
  BMC Cancer.2018;[Epub]     CrossRef
• Linker Variation and Structure–Activity Relationship Analyses of Carboxylic Acid-based Small Molecule STAT3 Inhibitors
  Francisco Lopez-Tapia, Christine Brotherton-Pleiss, Peibin Yue, Heide Murakami, Ana Carolina Costa Araujo, Bruna Reis dos Santos, Erin Ichinotsubo, Anna Rabkin, Raj Shah, Megan Lantz, Suzie Chen, Marcus A. Tius, James Turkson
  ACS Medicinal Chemistry Letters.2018; 9(3): 250.     CrossRef
• Decoy-Based, Targeted Inhibition of STAT3: A New Step forward for B Cell Lymphoma Immunotherapy
  Mario M. Soldevilla, Fernando Pastor
  Molecular Therapy.2018; 26(3): 675.     CrossRef
• Two decades of research in discovery of anticancer drugs targeting STAT3, how close are we?
  Jenny D. Beebe, Jing-Yuan Liu, Jian-Ting Zhang
  Pharmacology & Therapeutics.2018; 191: 74.     CrossRef
• Translational and clinical advances in JAK-STAT biology: The present and future of jakinibs
  Massimo Gadina, Catrina Johnson, Daniella Schwartz, Michael Bonelli, Sarfaraz Hasni, Yuka Kanno, Paul Changelian, Arian Laurence, John J O’Shea
  Journal of Leukocyte Biology.2018; 104(3): 499.     CrossRef
• Targeting JAK-STAT signal transduction in IBD
  Christoffer Soendergaard, Fredrik Holmberg Bergenheim, Jakob Tveiten Bjerrum, Ole Haagen Nielsen
  Pharmacology & Therapeutics.2018; 192: 100.     CrossRef
• “Do We Know Jack” About JAK? A Closer Look at JAK/STAT Signaling Pathway
  Emira Bousoik, Hamidreza Montazeri Aliabadi
  Frontiers in Oncology.2018;[Epub]     CrossRef
• Plasticity of Type I Interferon-Mediated Responses in Cancer Therapy: From Anti-tumor Immunity to Resistance
  Megha Budhwani, Roberta Mazzieri, Riccardo Dolcetti
  Frontiers in Oncology.2018;[Epub]     CrossRef
• STAT3 in Breast Cancer Onset and Progression: A Matter of Time and Context
  Ilenia Segatto, Gustavo Baldassarre, Barbara Belletti
  International Journal of Molecular Sciences.2018; 19(9): 2818.     CrossRef
• Suppression of STAT3 signaling promotes cellular reprogramming into insulin-producing cells induced by defined transcription factors
  Masaki Miura, Takeshi Miyatsuka, Takehiro Katahira, Shugo Sasaki, Luka Suzuki, Miwa Himuro, Yuya Nishida, Yoshio Fujitani, Taka-aki Matsuoka, Hirotaka Watada
  EBioMedicine.2018; 36: 358.     CrossRef
• Aptamer-iRNAs as Therapeutics for Cancer Treatment
  Mario M. Soldevilla, Daniel Meraviglia-Crivelli de Caso, Ashwathi P. Menon, Fernando Pastor
  Pharmaceuticals.2018; 11(4): 108.     CrossRef
• A First-in-Human Phase I Study of OPB-111077, a Small-Molecule STAT3 and Oxidative Phosphorylation Inhibitor, in Patients with Advanced Cancers
  Anthony Tolcher, Keith Flaherty, Geoffrey I. Shapiro, Jordan Berlin, Thomas Witzig, Thomas Habermann, Andrea Bullock, Edwin Rock, Agnes Elekes, Chester Lin, Dusan Kostic, Naoto Ohi, Drew Rasco, Kyriakos P. Papadopoulos, Amita Patnaik, Lon Smith, Gregory M
  The Oncologist.2018; 23(6): 658.     CrossRef
• Impact of STAT3 phosphorylation in glioblastoma stem cells radiosensitization and patient outcome
  Konstantin Masliantsev, Baptiste Pinel, Anaïs Balbous, Pierre-Olivier Guichet, Gaëlle Tachon, Serge Milin, Julie Godet, Mathilde Duchesne, Antoine Berger, Christos Petropoulos, Michel Wager, Lucie Karayan-Tapon
  Oncotarget.2018; 9(3): 3968.     CrossRef
• Discovery of an Orally Selective Inhibitor of Signal Transducer and Activator of Transcription 3 Using Advanced Multiple Ligand Simultaneous Docking
  Wenying Yu, Chenglong Li, Wenda Zhang, Yuanzheng Xia, Shanshan Li, Jia-yuh Lin, Keqin Yu, Mu Liu, Lei Yang, Jianguang Luo, Yijun Chen, Hongbin Sun, Lingyi Kong
  Journal of Medicinal Chemistry.2017; 60(7): 2718.     CrossRef
• Exploiting the Ref-1-APE1 node in cancer signaling and other diseases: from bench to clinic
  Fenil Shah, Derek Logsdon, Richard A. Messmann, Jill C. Fehrenbacher, Melissa L. Fishel, Mark R. Kelley
  npj Precision Oncology.2017;[Epub]     CrossRef
• Mitochondrial dysfunction induced by a SH2 domain-targeting STAT3 inhibitor leads to metabolic synthetic lethality in cancer cells
  Davide Genini, Lara Brambilla, Erik Laurini, Jessica Merulla, Gianluca Civenni, Shusil Pandit, Rocco D'Antuono, Laurent Perez, David E. Levy, Sabrina Pricl, Giuseppina M. Carbone, Carlo V. Catapano
  Proceedings of the National Academy of Sciences.2017;[Epub]     CrossRef
• Identification of novel small molecules that inhibit STAT3-dependent transcription and function
  Iryna Kolosenko, Yasmin Yu, Sander Busker, Matheus Dyczynski, Jianping Liu, Martin Haraldsson, Caroline Palm Apergi, Thomas Helleday, Katja Pokrovskaja Tamm, Brent D. G. Page, Dan Grander, Aamir Ahmad
  PLOS ONE.2017; 12(6): e0178844.     CrossRef
• Antineoplastic effects of CPPTL via the ROS/JNK pathway in acute myeloid leukemia
  Hui-Er Gao, Yue Sun, Ya-Hui Ding, Jing Long, Xiao-Lei Liu, Ming Yang, Qing Ji, Ying-Hui Li, Yue Chen, Quan Zhang, Ying-Dai Gao
  Oncotarget.2017; 8(24): 38990.     CrossRef
• Stattic and metformin inhibit brain tumor initiating cells by reducing STAT3-phosphorylation
  Verena Leidgens, Judith Proske, Lisa Rauer, Sylvia Moeckel, Kathrin Renner, Ulrich Bogdahn, Markus J. Riemenschneider, Martin Proescholdt, Arabel Vollmann-Zwerenz, Peter Hau, Corinna Seliger
  Oncotarget.2017; 8(5): 8250.     CrossRef
• Identification of antipsychotic drug fluspirilene as a potential anti-glioma stem cell drug
  Yu Dong, Takuya Furuta, Hemragul Sabit, Tomohiro Kitabayashi, Shabierjiang Jiapaer, Masahiko Kobayashi, Yasushi Ino, Tomoki Todo, Lei Teng, Atsushi Hirao, Shi-Guang Zhao, Mitsutoshi Nakada
  Oncotarget.2017; 8(67): 111728.     CrossRef
• Feedback Activation of STAT3 as a Cancer Drug-Resistance Mechanism
  Chengguang Zhao, Huameng Li, Huey-Jen Lin, Shulin Yang, Jiayuh Lin, Guang Liang
  Trends in Pharmacological Sciences.2016; 37(1): 47.     CrossRef
• Targeting transcription factor STAT3 for cancer prevention and therapy
  Edna Zhi Pei Chai, Muthu K. Shanmugam, Frank Arfuso, Arunasalam Dharmarajan, Chao Wang, Alan Prem Kumar, Ramar Perumal Samy, Lina H.K. Lim, Lingzhi Wang, Boon Cher Goh, Kwang Seok Ahn, Kam Man Hui, Gautam Sethi
  Pharmacology & Therapeutics.2016; 162: 86.     CrossRef
• Molecular Bases for Combinatorial Treatment Strategies in Patients with KRAS Mutant Lung Adenocarcinoma and Squamous Cell Lung Carcinoma
  Chiara Lazzari, Alberto Verlicchi, Anastasios Gkountakos, Sara Pilotto, Mariacarmela Santarpia, Imane Chaib, Jose Luis Ramirez Serrano, Santiago Viteri, Daniela Morales-Espinosa, Claudio Dazzi, Filippo de Marinis, Peng Cao, Niki Karachaliou, Rafael Rosell
  Pulmonary Therapy.2016; 2(1): 1.     CrossRef
• Preclinical Characterization of 3β-(N-Acetyl l-cysteine methyl ester)-2aβ,3-dihydrogaliellalactone (GPA512), a Prodrug of a Direct STAT3 Inhibitor for the Treatment of Prostate Cancer
  Zilma Escobar, Anders Bjartell, Giacomo Canesin, Susan Evans-Axelsson, Olov Sterner, Rebecka Hellsten, Martin H Johansson
  Journal of Medicinal Chemistry.2016; 59(10): 4551.     CrossRef
• A Positive TGF-β/c-KIT Feedback Loop Drives Tumor Progression in Advanced Primary Liver Cancer
  Andres Rojas, Pingyu Zhang, Ying Wang, Wai Chin Foo, Nina M. Muñoz, Lianchun Xiao, Jing Wang, Gregory J. Gores, Mien-Chie Hung, Boris Blechacz
  Neoplasia.2016; 18(6): 371.     CrossRef
• Novel STAT 3 inhibitors for treating gastric cancer
  Catherine Cafferkey, Ian Chau
  Expert Opinion on Investigational Drugs.2016; 25(9): 1023.     CrossRef
• ‘Acute myeloid leukemia: a comprehensive review and 2016 update’
  I De Kouchkovsky, M Abdul-Hay
  Blood Cancer Journal.2016; 6(7): e441.     CrossRef
• Recent updates of precision therapy for gastric cancer: Towards optimal tailored management
  Moon Kyung Joo, Jong-Jae Park, Hoon Jai Chun
  World Journal of Gastroenterology.2016; 22(19): 4638.     CrossRef
• Targeted inhibition of STATs and IRFs as a potential treatment strategy in cardiovascular disease
  Malgorzata Szelag, Anna Piaszyk-Borychowska, Martyna Plens-Galaska, Joanna Wesoly, Hans A.R. Bluyssen
  Oncotarget.2016; 7(30): 48788.     CrossRef
• Cell-cell and cell-matrix adhesion in survival and metastasis: Stat3 versus Akt
  Maximilian Niit, Victoria Hoskin, Esther Carefoot, Mulu Geletu, Rozanne Arulanandam, Bruce Elliott, Leda Raptis
  Biomolecular Concepts.2015; 6(5-6): 383.     CrossRef
• Phase 1 and pharmacological trial of OPB‐31121, a signal transducer and activator of transcription‐3 inhibitor, in patients with advanced hepatocellular carcinoma
  Takuji Okusaka, Hideki Ueno, Masafumi Ikeda, Shuichi Mitsunaga, Masato Ozaka, Hiroshi Ishii, Osamu Yokosuka, Yoshihiko Ooka, Ryo Yoshimoto, Yasuo Yanagihara, Kiwamu Okita
  Hepatology Research.2015; 45(13): 1283.     CrossRef
• STAT3 Inhibition Enhances the Therapeutic Efficacy of Immunogenic Chemotherapy by Stimulating Type 1 Interferon Production by Cancer Cells
  Heng Yang, Takahiro Yamazaki, Federico Pietrocola, Heng Zhou, Laurence Zitvogel, Yuting Ma, Guido Kroemer
  Cancer Research.2015; 75(18): 3812.     CrossRef